- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 153949 |
Antigen/Gene or Protein Targets | Escherichia coli cells cannot metabolize xylose, glucose nor arabinose. |
Classification | Escherichia coli |
Bacterial Resistance | Kanamycin |
Relevance | Microbial fermentation processes are used to generate a myriad of comedic chemicals representing market segments valued in the billions of dollars. Microbial metabolic pathways are not though, naturally optimal for the generation of a desired chemical, rather they have evolved for the benefit of the organism. Metabolic engineering is the targeted and rational alteration of metabolism, and it involves the redirection of intra-cellular processes to generate a new product or a product in much higher yields and/or faster rates. UGA researchers have developed a collection of engineered E. coli strains that are capable of (i) producing pyruvate, (ii) used in the co-fermentation – at the same rate - of mixed pentoses and hexoses, or (iii) reducing the formation of acetate by-product of fermentations, under different metabolic conditions. These strains are optimal starting points for the development of novel derivative strains for industrial use |
Genomic Feature | C (ATCC8739) ptsG763::(FRT) glk-726::(FRT) manZ743::(FRT) crr-746::(FRT) xylA726::(FRT)Kan araA::(FRT) |
Notes | Lysogeny broth: 10g/L tryptone, 10g/L NaCl, 5g/L yeast extract, pH adjusted to 7.0, aerobic 37C. Provided as lyophilized culture. |
Research Area | Metabolism, Microbiology, Bacteriology |
References: 2 entries
Xia et al. 2012. Microb Cell Fact. 11:77. PMID: 22691294.
Simultaneous utilization of glucose, xylose and arabinose in the presence of acetate by a consortium of Escherichia coli strains.
Europe PMC ID: 22691294
Add a reference
References: 2 entries
Xia et al. 2012. Microb Cell Fact. 11:77. PMID: 22691294.
Simultaneous utilization of glucose, xylose and arabinose in the presence of acetate by a consortium of Escherichia coli strains.
Add a reference
Inventor Information
Inventors
|
Mark Eiteman |